Ellen de Brabander - 01 Mar 2022 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Reporting relationship: Executive Vice President of Innovation and Regulatory Affairs
Issuer ticker: ELAN
Reported as of: 01 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2022, 19:58:45 UTC
Prior SEC filing: 08 Nov 2021
Next SEC filing: 03 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Collin Smyser, Attorney-in-Fact for Ellen de Brabander

Key filing fact

Ellen de Brabander filed Form 4 for Elanco Animal Health Inc (ELAN) on 03 Mar 2022.

Key facts

This page summarizes Ellen de Brabander's Form 4 filing for Elanco Animal Health Inc (ELAN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2022, 19:58.

Change

Previous filing in this sequence was filed on 08 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELAN transaction

Common Stock

Award

Transaction value: $0
Shares: +14,496
Change %: +32%
Price: $0.000000
Shares after: 60,131
Date: 01 Mar 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELAN transaction Derivative

Employee Stock Option(right to buy)

Award

Transaction value: $0
Shares: +38,522
Change %
Price: $0.000000
Shares after: 38,522
Date: 01 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,522
Exercise price: $28.94
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of restricted stock units pursuant to the Amended and Restated 2018 Elanco Stock Plan on March 1, 2022, one-third vesting on March 1, 2023, one-third vesting on March 1, 2024, and the remaining vesting on March 1, 2025.

Footnote F2

Grant of stock options vesting as follows: one-third vesting on March 1, 2023, one-third vesting on March 1, 2024, and the remaining vesting on March 1, 2025.

SEC remarks

Executive Vice President of Innovation and Regulatory Affairs